Yes, sleepiness (somnolence) is a documented side effect of Vraylar (cariprazine)
According to the FDA drug label, somnolence occurs in 6-11% of Vraylar-treated patients compared to 4-6% of placebo-treated patients across different indications, representing a clinically meaningful increase in sleepiness risk. 1
Incidence Rates by Indication
The FDA label provides specific somnolence rates across clinical trials:
- Schizophrenia (6-week trials): 7% with Vraylar vs. 6% with placebo
- Bipolar mania (3-week trials): 8% with Vraylar vs. 4% with placebo
- Bipolar depression (6-8 week trials): 7% with Vraylar vs. 4% with placebo
- Major depressive disorder adjunctive (6-week trials): 6% with Vraylar vs. 4% with placebo
- Major depressive disorder adjunctive (8-week trial): 11% with Vraylar vs. 6% with placebo 1
Clinical Significance and Safety Considerations
The FDA explicitly warns that Vraylar may cause somnolence and has the potential to impair judgment, thinking, or motor skills. Patients must be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that Vraylar does not affect them adversely. 1
Important Safety Context
Somnolence with Vraylar contributes to additional risks:
Falls risk: The combination of somnolence, postural hypotension, and motor/sensory instability increases fall risk, particularly concerning in elderly patients or those with conditions that exacerbate these effects 1
Dose-dependent considerations: While the FDA label doesn't specify clear dose-response relationships for somnolence specifically, recent pooled analyses in major depressive disorder show that akathisia and insomnia demonstrated potential dose-dependent responses 2
Comparative Profile
Cariprazine is clinically classified as a "low-somnolence" drug relative to other atypical antipsychotics 3, which is reflected in the relatively modest difference from placebo (typically 2-5 percentage points). This distinguishes it from more sedating antipsychotics like quetiapine, olanzapine, or clozapine, which have higher central anticholinergic activity and greater sedation risk 4.
Recent research confirms cariprazine's relatively favorable tolerability profile, with most treatment-emergent adverse events being mild to moderate 2. In real-world settings, cariprazine demonstrates high study completion rates (90%) and low discontinuation rates due to adverse events (4.3%) 2.
Clinical Management Recommendations
When prescribing Vraylar:
- Warn patients explicitly about potential somnolence and driving/machinery operation risks
- Assess fall risk at treatment initiation and recurrently during long-term therapy, especially in elderly patients or those with comorbid conditions 1
- Monitor for excessive sedation particularly during dose titration
- Consider timing of administration (though not specified in the label, evening dosing may minimize daytime impairment if somnolence occurs)
- Evaluate for contributing factors if problematic sedation develops (drug interactions, concurrent CNS depressants, underlying sleep disorders)
The somnolence risk with Vraylar is real but generally manageable, occurring at rates only modestly higher than placebo across most indications.